Analyst: Positive data ease partner search
New positive data will aid Topotarget in its search for a European partner for a promising candidate drug, says an analyst. Although the price is going up, he still believes that the share is lower than it should be.
by Leonora Beck
New data for candidate drug, Belinostat, published by Danish biotech Topotarget on Thursday will bring with it a number of positive side effects, says analyst Mick Cooper from London, UK-based Edison Investment Research Limited.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Topotarget-CEO: Orphan-status eases partner search
For abonnenter
Topotarget-medicine gets Orphan Drug-status
For abonnenter
.jpg&w=384&q=75){kind=logo}
